Company news
Sareum Holdings Plc (LSE:SAR) news
Sareum Holdings Plc news releases on 6ix. Latest, Apr 23, 2019: SRA737 Phase I/IIa data to be presented at ASCO
Press releases — page 4
SRA737 Phase I/IIa data to be presented at ASCO
April 23, 2019
Preclinical Data for SRA737 Presented at AACR 2019
April 2, 2019
Sareum Holdings PLC Issue of Options
March 12, 2019
HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
March 4, 2019
Sierra Oncology has reported its 2018 Results
February 28, 2019
New SRA737 preclin data to be presented at AACR
February 28, 2019
Sierra Oncology to present SRA737 at DDR Tx Summit
January 23, 2019
Amendment to Preclinical Efficacy Announcement
November 30, 2018
Preclinical Efficacy for Immunotherapy Combination
November 30, 2018
Preclinical Data for SRA737 in Ovarian Cancer
November 15, 2018
AGM NOTICE
November 14, 2018
Directorate Change
November 13, 2018
Sierra Oncology Q3 2018 Results
November 8, 2018
Completion of Placing
October 26, 2018
FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
October 1, 2018
Notice of Results
September 27, 2018
TYK2/JAK1 selected for certain cancers
September 26, 2018
Pre-Close Trading Statement
September 11, 2018
Selection of TYK2/JAK1 for autoimmune diseases
September 10, 2018
Sareum notes Sierra Oncology Q2 2018 Results
August 9, 2018
Notification of PCA Shareholding
July 11, 2018
Advisers
June 15, 2018
Sareum regains rights to Aurora+FLT3 inhibitors
May 31, 2018
SRA737 trial update in Sierra Oncology Q1 Results
May 10, 2018
Sareum to Present at BioTrinity 2018 in London
April 24, 2018
AACR 2018 Update
April 17, 2018
Late-breaker abstract for SRA737 accepted for AACR
March 15, 2018
Interim Results
March 13, 2018
Sierra Oncology expands SRA737 development program
February 27, 2018
Preclinical synergy of sra737 and PARP inhibitor
February 22, 2018
Notice of Interim Results
February 13, 2018
Issue of Options
December 20, 2017
Patent Grants in Japan & China for TYK2 Inhibitors
December 19, 2017
Notice of AGM and Annual Report & Accounts
November 20, 2017
Placing
November 14, 2017
Sierra Reports Preclinical Data for Chk1 Inhibitor
October 31, 2017
Sierra Oncology host KOL Meeting on 12 Oct in NY
October 9, 2017
Sierra Oncology to host call on Chk1 inhibitor
September 18, 2017
Sareum to Present at the ICCS 2017
June 19, 2017
Chk1 Clinical Trials Update
June 5, 2017
Sierra Oncology Granted US and EU Patents
May 31, 2017
Sierra Oncology to Present at ASCO Annual Meeting
May 25, 2017
Sareum to Present at BioTrinity 2017
May 9, 2017
Director Shareholding
March 9, 2017
Half-year Results
February 20, 2017
Milestone Payment from Chk1 Licence Agreement
January 9, 2017
Result of General Meeting
December 22, 2016
Directors' Remuneration & General Meeting
December 6, 2016
Sareum to Present at AACR-NCI-EORTC Conference
November 29, 2016
Successful Outcome from TYK2 Feasibility Study
October 24, 2016